Philip S. Low
Next Generation Targeted Therapeutics
Lab Members
Philip Low
Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low has spent over 50 years exploring:
- targeted therapeutic and imaging agents for multiple human diseases (including cancer, autoimmune, infectious, inherited, and inflammatory diseases),
- the structure, function, and pathologies of the erythrocyte membrane, and
- signal transduction across plant cell membranes.
He has published over 500 scientific articles and has over 700 US patents/patents pending. Stemming from his research, he has three FDA-approved drugs on the market, five drugs undergoing human clinical trials and eight companies (Endocyte Inc., OnTarget Laboratories Inc., Quince Therapeutics Inc., Umoja Biopharma, Eradivir Inc., Morphimmune Inc., ErythroCure Inc., and LIFT / Low Institute for Therapeutics) that have been founded to commercialize these discoveries. Dr. Low received his B.S. in Chemistry from BYU (1971) and his Ph.D. in Biochemistry from UCSD (1975).
Email: plow@purdue.edu
Staff
|
Madduri Srinivasarao Research Assistant Professor |
Patricia Cauble Operations Administrator |
Suzy Gustafson Senior Administrative Assistant |
|
Ramesh Mukkamala Associate Research Scientist Design and development of Fibroblast Activation Protein (FAP) targeted ligands and their applications for delivery of attached imaging and therapeutic agents to cancers and fibrotic diseases.
|
Sudarsan Reddy Kasireddy Associate Research Scientist Design, synthesis, and evaluation of ligand-targeted oligonucleotides and therapeutic agents for the treatment of cancer and fibrotic diseases.
|
Suilan Zheng Research Scientist Design of novel CAR T cell (Chimeric Antigen Receptor T cell) based immunotherapies for solid tumors that can be sensitively and continuously regulated following their infusion into cancer patients.
|
|
Suresh Yarlagadda Associate Research Scientist Design, Synthesis, and Biological Evaluation of Novel Spleen Tyrosine Kinase Inhibitors for the Treatment of Autoimmune, Inflammatory and Cancerous Diseases.
|
Zanna Larson Research Technician Development of precision therapeutics aimed at treating viral infections, cancer, and autoimmune diseases
|
Sakkarapalayam M. Mahalingam Research Scientist Design, synthesis and preclinical evaluation of tumor targeted near infra-red dyes for the fluorescence guided surgeries of cancers. Also working on extending the half-life of therapeutics by developing RBC membrane protein binders and plasma protein binders. |
|
Mahesh Kumar Rao Yelineni Research Scientist Development of Folate-Targeted Steroids and Vaccine Conjugates for the Treatment of Autoimmune, Inflammatory, and Cancer Disorders |
|
Pragnya Athri Research Assistant Expansion of bispecific antigenic immunotherapy (BAiT) platform for the treatment of kidney cancer and hematologic malignancies. |
Group Members
Visiting Scholars
|
Jeffery Nielsen, Vice President of Research and Development at Eradivir Visiting Scholar Developing small molecule targeted immunotherapies to harness the power of the immune system to clear viral infections and cancers. Currently developing therapeutics for treating influenza, RSV, and Dengue. |
Spencer Lindeman, Director of Medicinal Chemistry at Eradivir Visiting Scholar Discovery and development of next generation, small molecule-based immunotherapies for the treatment of cancer, fibrosis, infectious, and autoimmune diseases |
Ananda Kumar Kanduluru, Director of Research & Development at Eradivir Visiting Scholar Design and development of targeted therapeutic agents for multiple diseases including infectious (anti viral’s), cancer and autoimmune diseases
|
|
Conrrad Nicholls, Scientist I at Eradivir Visiting Scholar Applying the immune activating dual hapten technology developed in the Low lab to virus infections, including RSV and dengue virus.
|
Charity Campbell, Clinical Research Associate at Eradivir Visiting Scholar
|
Imrul Shahriar, Scientist I at Eradivir Visiting Scholar Development of a bispecific immune cell engager platform with applications in cancer, autoimmune, fibrotic, and infectious diseases |
|
Stewart Low, Executive Director at Low Institute for Therapeutics (LIFT) Visiting Scholar Cultivate an R&D pipeline from preclinical studies through clinical development and regulatory submission.
|
|
Mary Niedrauer, Senior Director at Low Institute for Therapeutics (LIFT) Visiting Scholar Development of drug candidates from discovery through early clinical trials across disease states, including cancer, autoimmune, and fibrotic diseases. |
|
Losha DaSol Jung, Scientist I at Low Institute for Therapeutics (LIFT) Visiting Scholar Lead the design and execution of comprehensive preclinical studies in in vitro, ex vivo, and in vivomodels to support the development of novel targeted cancer therapies.
|
Jennifer Clark, Research Associate for Low Institute for Therapeutics (LIFT) Visiting Scholar Development and execution of preclinical studies in order to to precisely treat a wide range of diseases by preferentially targeting diseased tissue. |
Reuben Dass, Scientist I at Low Institute for Therapeutics (LIFT) Visiting Scholar Design, optimization, and evaluation of novel therapeutic agents, with a focus on enhancing their selectivity, efficacy, and pharmacokinetic properties through detailed structure–activity relationship (SAR) studies.
|
Post-Doctorates
|
Ranjith Kumar Gadi Post-Doctorate Extending the half-life of therapeutics through the development of RBC binders and plasma protein binders, as well as design and synthesizing stable linkers for FRET-based small-molecule probes
|
Ronard Kwizera Post-Doctorate Design, synthesis, and evaluation of therapeutic activity of targeted immunotherapies for difficult-to-treat human diseases such as cancer. |
Ravikumar Reddy Chatrala Post-Doctorate Development of Folate Conjugates for Imaging and Therapeutic Agents to Cancers Overexpressing Folate Receptors, Aiming to Improve Tumor Specificity and Reduce Off-Target Effects
|
|
|
Biswajit Sen Post-Doctorate Development and synthesis of GalNAc-conjugates with various rigid linkers and small drug molecules for treating non-alcoholic steatohepatitis (NASH) and other liver diseases. |
|
Graduate Students
|
Jacob David Newey Ph.D. Graduate Student Design, synthesis, and testing of targeted antigens for the treatment of autoimmune diseases and allergies.
|
Charles Key Stone Ph.D. Graduate Student Development, synthesis and testing of small molecule immunotherapies targeting Natural Killer cells and Neutrophils for the treatment of Cancer and Autoimmune diseases.
|
Christopher Jensen Ph.D. Graduate Student Development of applications for steroids targeted to activated macrophages in the treatment of autoimmune and inflammatory diseases. |
|
Pranav Ballaney Ph.D. Graduate Student Computational design, synthesis, and preclinical evaluation immune cell engagers with applications in cancer and autoimmune disorders.
|
Zhixia Chi Ph.D. Graduate Student Design and develop new ligand-conjugated antisense oligonucleotides for preclinical studies of fibrotic diseases, with a focus on renal fibrosis |
Mohammed Yusuf Al Amin Ph.D. Graduate Student Development of cytokine inhibitory drugs targeting (a) tumor associated macrophages (TAMs) and cancer associated fibroblasts (CAFs) in the management of cancer, and (b) activated macrophages and fibroblasts in the treatment of fibrosis.
|
|
Shomoita Sayed Ph.D. Graduate Student Development and Optimization of targeted novel therapeutics for the treatment of retinal diseases. |
Yingqi Chen Ph.D. Graduate Student Design and development of an antigen, targeting ligand, and adjuvant integrated into a single universal dendritic cell (DC) targeting vaccine for use in cancer and infectious disease models. |
Hunter Hutson Ph.D. Graduate Student Design and development of small molecule targeted therapeutics for the treatment of CNS diseases. |
|
Kavya Ananthaswamy Ph.D. Graduate Student
|
Mohammed Sazzadul Bari Ph.D. Graduate Student Designing and development of novel therapeutics for treating different fibrotic diseases and cancer by creating drug conjugates that specifically target proteins overexpressed on activated fibroblasts, aiming to maximize therapeutic efficacy while minimizing off-target interactions. |
Qingshi Chen Ph.D. Graduate Student Design and development of small molecule targeted therapeutics for the treatment of atherosclerosis. |
|
Cameron Smith Ph.D. Graduate Student Development and characterization of small molecule drug conjugates for targeting and repolarizing TAMs in the tumor microenvironment for the treatment of cancer. |
Haowei Xu Ph.D. Graduate Student Development of targeted therapeutics to alleviate obesity and renal transplant rejection
|
Roman Slowinski Ph.D. Graduate Student Developing molecular shuttling systems to transport therapeutics across the Blood-Brain Barrier. |
|
|
Archit Gupta Ph.D. Graduate Student Advancing targeted drug and RNA-based therapies for cancer treatment |
|
